Serum Phosphorus and Cardiovascular Mortality in Type 2 Diabetes

被引:54
作者
Chonchol, Michel [1 ]
Dale, Rita [2 ]
Schrier, Robert W. [1 ]
Estacio, Raymond [3 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Denver, CO 80262 USA
[2] Colorado Prevent Ctr, Denver, CO USA
[3] Denver Hlth, Dept Internal Med, Denver, CO USA
关键词
Calcium; Calcium-phosphorus product; Cardiovascular disease; Cardiovascular mortality; Phosphorus; Type; 2; diabetes; MYOCARDIAL-INFARCTION; HEMODIALYSIS-PATIENTS; ARTERY CALCIFICATION; DISEASE RISK; CALCIUM; ASSOCIATION; CHOLESTEROL; PROGNOSIS; SURVIVAL; OLDER;
D O I
10.1016/j.amjmed.2008.09.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Although serum phosphorus, calcium, and calcium-phosphorus product levels have been associated with cardiovascular events and mortality in patients with normal kidney function, most studies have not examined the association of these minerals with outcomes when collected repeatedly over time. METHODS: We evaluated the association of serum phosphorus, calcium, and calcium-phosphorus product levels with cardiovascular events and mortality in 950 participants of the Appropriate Blood Pressure Control in Diabetes trial by both time-dependent Cox regression models using the cumulative average of minerals measured over time and fixed covariate Cox regression models with only baseline values of these minerals. RESULTS: There were 42 deaths and 193 cardiovascular events among the participants, who were followed for an average of 4.8 years following randomization. A significant association was noted between baseline serum phosphorus >3.9 mg/dL and baseline calcium-phosphorus product >36.8 mg(2)/dL(2) compared with the lowest referent category with the adjusted risk of cardiovascular death (hazard ratio [HR] 5.00; 95% confidence interval [CI], 1.70-14.72) and (HR 10.01; 95% CI, 2.55-39.31), respectively. However, in time-dependent models using mineral values repeated during the course of the study, only the average of serum phosphorus remains significant (HR 4.25; 95% CI, 1.15 to 16.65). CONCLUSIONS: In the Appropriate Blood Pressure Control in Diabetes cohort, serum phosphorus, but not serum calcium or calcium-phosphorus product, was associated with cardiovascular mortality in time-dependent Cox regression models. Thus, serum phosphorus levels may be more reliable in predicting cardiovascular mortality in patients with type 2 diabetes. (C) 2009 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2009) 122, 380-386
引用
收藏
页码:380 / 386
页数:7
相关论文
共 26 条
[1]  
Bellasi Antonio, 2006, Hemodial Int, V10, P225, DOI 10.1111/j.1542-4758.2006.00100.x
[2]   Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients [J].
Block, G. A. ;
Raggi, P. ;
Bellasi, A. ;
Kooienga, L. ;
Spiegel, D. M. .
KIDNEY INTERNATIONAL, 2007, 71 (05) :438-441
[3]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[4]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[5]   Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis) [J].
Block, GA .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (06) :741-747
[6]   Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [J].
Curb, JD ;
Pressel, SL ;
Cutler, JA ;
Savage, PJ ;
Applegate, WB ;
Black, H ;
Camel, G ;
Davis, BR ;
Frost, PH ;
Gonzalez, N ;
Guthrie, G ;
Oberman, A ;
Rutan, GH ;
Stamler, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (23) :1886-1892
[7]   Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community [J].
Dhingra, Ravi ;
Sullivan, Lisa M. ;
Fox, Caroline S. ;
Wang, Thomas J. ;
D'Agostino, Ralph B. ;
Gaziano, J. Michael ;
Vasan, Ramachandran S. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (09) :879-885
[8]   Molecular, endocrine, and genetic mechanisms of arterial calcification [J].
Doherty, TM ;
Fitzpatrick, LA ;
Inoue, D ;
Qiao, JH ;
Fishbein, MC ;
Detrano, RC ;
Shah, PK ;
Rajavashisth, TB .
ENDOCRINE REVIEWS, 2004, 25 (04) :629-672
[9]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[10]   The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension [J].
Estacio, RO ;
Jeffers, BW ;
Hiatt, WR ;
Biggerstaff, SL ;
Gifford, N ;
Schrier, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (10) :645-652